However, a phase I/II trial evaluating the safety and efficacy of the AKT inhibitor ipatasertib in combination with the PARP inhibitor rucaparib in patients with advanced breast, ovarian and prostate cancer is currently recruiting and should provide invaluable insight into the efficacy of this combination in the setting of advanced prostate cancer (NCT03840200). This evidence concerns the gene AKT1 and Familial prostate cancer.